We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
CASPOCIP, CASPOFUNGIN CA, CASPOFUNGIN CIPLA (Cipla Australia Pty Ltd)
Product name
CASPOCIP, CASPOFUNGIN CA, CASPOFUNGIN CIPLA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
189 working days (255)
Active ingredients
caspofungin (as acetate)
Registration type
New generic medicine
Indication
CASPOCIP/CASPOFUNGIN CA/CASPOFUNGIN CIPLA (powder for injection) is indicated for the treatment of presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics. It is indicated for the treatment of invasive candidiasis, including candidaemia; oesophageal candidiasis; and invasive aspergillosis in patients who are refractory to, or intolerant of, other therapies.